Company: EDSA
Filing Date: 2025-03-04
Form Type: S-3
Source: 0001171843-25-001239
Chunk: 14

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-04
Form: S-3
Chunk 14
---
 Preferred Shares owned by them and, if they default in the performance of
their secured obligations, the pledgees or secured parties may offer and sell the Shares or Conversion Shares, from time to time, under
this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending
the list of Selling Shareholders to include the pledgee, transferee or other successors in interest as Selling Shareholders under this
prospectus. The Selling Shareholders also may transfer the Shares or Conversion Shares in other circumstances, in which case the transferees,
pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

In connection with the sale of the Shares, Conversion
Shares or interests therein, the Selling Shareholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the Shares or the Conversion Shares in the course of hedging the positions they assume. The
Selling Shareholders may also sell the Shares or the Conversion Shares short and deliver these securities to close out their short positions,
or loan or pledge the Shares or the Conversion Shares to broker-dealers that in turn may sell these securities. The Selling Shareholders
may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which
shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect
such transaction).

The aggregate proceeds to the Selling Shareholders
from the sale of the Shares or the Conversion Shares offered by them will be the purchase price of the Shares or the Conversion Shares
less discounts or commissions, if any. Each of the Selling Shareholders reserves the right to accept and, together with their agents from
time to time, to reject, in whole or in part, any proposed purchase of the Shares or the Conversion Shares to be made directly or through
agents. We will not receive any of the proceeds from this offering.

| 12 |

The Selling Shareholders and any underwriters, broker-dealers
or agents that participate in the sale of the Shares, the Conversion Shares or interests therein may be “underwriters” within
the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they